# Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer

> **NCT06522919** · PHASE2 · RECRUITING · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 36 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic
- Microsatellite Stable Colorectal Carcinoma
- Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Autologous Dendritic Cell (DC) Vaccine

## Key facts

- **NCT ID:** NCT06522919
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-07
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06522919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06522919, "Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06522919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*